For individuals aged 35 years, if SGLT2 inhibitors were less effective at reducing all-cause mortality (HR for those without diabetes, 0.86; HR for those with diabetes, 0.98 vs base-case values of 0.54 and 0.75, respectively), the ICER for screening every 5 years from age 35 years increased to more than $250 000 per QALY gained, and the ICER for waiting to initiate screening at age 55 years increased to more than $200 000 per QALY gained (Figure 3). This evidence concerns the gene SLC5A2 and diabetes mellitus.